Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06425991 | A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma(MajesTEC-10) | active not recruiting | Phase 1 | 108 | Janssen Research & Development, LLCINDUSTRY | 11 | Sep 28, 2026 | clinicaltrials |
| NCT06524375 | A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period(BRAVE) | active not recruiting | Phase 2 | 118 | Genentech, Inc. |
| 1 |
| Sep 28, 2026 |
| clinicaltrials |
| NCT06619236 | Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer(RAINFOL-02) | active not recruiting | Phase 3 | 584 | GenmabINDUSTRY | 18 | Sep 28, 2026 | clinicaltrials |
| NCT06625203 | A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology(MOSAIC) | active not recruiting | — | 7,000 | OWKINUNKNOWN | 4 | Sep 28, 2026 | clinicaltrials |
| NCT06651229 | A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms | active not recruiting | Phase 1 | 85 | Janssen Research & Development, LLCINDUSTRY | 3 | Sep 28, 2026 | clinicaltrials |
| NCT02123758 | A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 1 | 57 | Aragon Pharmaceuticals, Inc.INDUSTRY | 4 | Sep 25, 2026 | clinicaltrials |
| NCT02498613 | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors | active not recruiting | Phase 2 | 122 | National Cancer Institute (NCI)NIH | 2 | Sep 25, 2026 | clinicaltrials |
| NCT02538198 | Lenalidomide Maintenance in Plasma Cell Myeloma | active not recruiting | Phase 2 | 108 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT02595931 | M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | active not recruiting | Phase 1 | 66 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
| NCT02609776 | Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer(CHRYSALIS) | active not recruiting | Phase 1 | 751 | Janssen Research & Development, LLCINDUSTRY | 10 | Sep 25, 2026 | clinicaltrials |
| NCT02923778 | Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery | active not recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 2 | Sep 25, 2026 | clinicaltrials |
| NCT02994069 | Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers | active not recruiting | Phase 2 | 80 | Susanne ArnoldOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03145181 | Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma(MajesTEC-1) | active not recruiting | Phase 1 | 302 | Janssen Research & Development, LLCINDUSTRY | 5 | Sep 25, 2026 | clinicaltrials |
| NCT03399799 | Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma(MonumenTAL-1) | active not recruiting | Phase 1 | 279 | Janssen Research & Development, LLCINDUSTRY | 4 | Sep 25, 2026 | clinicaltrials |
| NCT03779854 | Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 2 | 45 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04108195 | A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma | active not recruiting | Phase 1 | 290 | Janssen Research & Development, LLCINDUSTRY | 5 | Sep 25, 2026 | clinicaltrials |
| NCT04123379 | Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) | active not recruiting | Phase 2 | 48 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04133636 | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma(CARTITUDE-2) | active not recruiting | Phase 2 | 208 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT04594642 | A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 226 | AstraZenecaINDUSTRY | 5 | Sep 25, 2026 | clinicaltrials |
| NCT04679012 | Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation | active not recruiting | Phase 2 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04876248 | Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant | active not recruiting | Phase 2 | 4 | Roswell Park Cancer InstituteOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04923893 | A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy(CARTITUDE-5) | active not recruiting | Phase 3 | 743 | Janssen Research & Development, LLCINDUSTRY | 26 | Sep 25, 2026 | clinicaltrials |
| NCT05023980 | A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(BRUIN-CLL-313) | active not recruiting | Phase 3 | 282 | Loxo Oncology, Inc.INDUSTRY | 20 | Sep 25, 2026 | clinicaltrials |
| NCT05083169 | A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma(MajesTEC-3) | active not recruiting | Phase 3 | 587 | Janssen Research & Development, LLCINDUSTRY | 21 | Sep 25, 2026 | clinicaltrials |
| NCT05132075 | Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer(KontRASt-02) | active not recruiting | Phase 3 | 95 | Novartis PharmaceuticalsINDUSTRY | 25 | Sep 25, 2026 | clinicaltrials |
| NCT05316155 | Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer | active not recruiting | Phase 1 / Phase 2 | 235 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT05430802 | Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIA-IIIB Resectable NSCLC (FORESEE) | active not recruiting | Phase 2 | 40 | Tang-Du HospitalOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05438043 | A Study of Daratumumab | active not recruiting | Phase 3 | 213 | Janssen Research & Development, LLCINDUSTRY | 17 | Sep 25, 2026 | clinicaltrials |
| NCT05453903 | A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies | active not recruiting | Phase 1 | 196 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT05455320 | A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment(MonumenTAL-3) | active not recruiting | Phase 3 | 864 | Janssen Research & Development, LLCINDUSTRY | 18 | Sep 25, 2026 | clinicaltrials |
| NCT05488314 | A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer(METalmark) | active not recruiting | Phase 1 / Phase 2 | 57 | Janssen Research & Development, LLCINDUSTRY | 13 | Sep 25, 2026 | clinicaltrials |
| NCT05548062 | Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera(Prospero) | active not recruiting | — | 242 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05572229 | Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma(IFM2021-01) | active not recruiting | Phase 2 | 74 | University Hospital, LilleOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05610163 | Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response(JANUS) | active not recruiting | Phase 2 / Phase 3 | 760 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 25, 2026 | clinicaltrials |
| NCT05647122 | First in Human Study of AZD9592 in Solid Tumors(EGRET) | active not recruiting | Phase 1 | 190 | AstraZenecaINDUSTRY | 11 | Sep 25, 2026 | clinicaltrials |
| NCT05663866 | Premedication to Reduce Amivantamab Associated Infusion Related Reactions | active not recruiting | Phase 2 | 68 | Janssen Research & Development, LLCINDUSTRY | 5 | Sep 25, 2026 | clinicaltrials |
| NCT05783596 | Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma | active not recruiting | Phase 2 | 47 | Reid Merryman, MDOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05784441 | A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) | active not recruiting | Phase 1 | 21 | Janssen Research & Development, LLCINDUSTRY | 4 | Sep 25, 2026 | clinicaltrials |
| NCT05908734 | A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer(PolyDamas) | active not recruiting | Phase 1 / Phase 2 | 71 | Janssen Research & Development, LLCINDUSTRY | 9 | Sep 25, 2026 | clinicaltrials |
| NCT05922930 | Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05963074 | A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia(TAILOR) | active not recruiting | Phase 2 | 333 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT06106360 | A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy | active not recruiting | — | 53 | Inova Health Care ServicesOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06116786 | A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 67 | Johnson & Johnson Enterprise Innovation Inc.INDUSTRY | 4 | Sep 25, 2026 | clinicaltrials |
| NCT06120140 | Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib(COCOON) | active not recruiting | Phase 2 | 305 | Janssen Research & Development, LLCINDUSTRY | 11 | Sep 25, 2026 | clinicaltrials |
| NCT06139406 | A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer | active not recruiting | Phase 1 | 70 | Janssen Research & Development, LLCINDUSTRY | 4 | Sep 25, 2026 | clinicaltrials |
| NCT06169215 | Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06208150 | A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide(MonumenTAL-6) | active not recruiting | Phase 3 | 838 | Janssen Research & Development, LLCINDUSTRY | 27 | Sep 25, 2026 | clinicaltrials |
| NCT06211764 | A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)(SunRISe-5) | active not recruiting | Phase 3 | 272 | Janssen Research & Development, LLCINDUSTRY | 14 | Sep 25, 2026 | clinicaltrials |
| NCT06284122 | Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5(MorningLyte) | active not recruiting | Phase 3 | 790 | The Lymphoma Academic Research OrganisationOTHER | 7 | Sep 25, 2026 | clinicaltrials |
| NCT06308419 | A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions | active not recruiting | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials